- Report
- July 2025
- 200 Pages
Japan
From €2243EUR$2,490USD£1,979GBP
- Report
- July 2025
- 200 Pages
Japan
From €2243EUR$2,490USD£1,979GBP
- Report
- June 2025
- 200 Pages
Saudi Arabia
From €2243EUR$2,490USD£1,979GBP
- Report
- June 2025
- 200 Pages
Japan
From €2243EUR$2,490USD£1,979GBP
- Report
- October 2024
- 200 Pages
United States
From €2243EUR$2,490USD£1,979GBP
- Report
- October 2024
- 200 Pages
Europe
From €2243EUR$2,490USD£1,979GBP
- Report
- July 2024
- 190 Pages
Global
From €2243EUR$2,490USD£1,979GBP
- Report
- February 2024
- 200 Pages
Global
From €1711EUR$1,900USD£1,510GBP
- Report
- February 2025
- 80 Pages
India
From €2243EUR$2,490USD£1,979GBP
- Report
- November 2024
- 100 Pages
Global
From €2243EUR$2,490USD£1,979GBP
- Report
- July 2024
- 152 Pages
Global
From €4279EUR$4,750USD£3,775GBP
- Report
- April 2023
- 111 Pages
Global
From €4279EUR$4,750USD£3,775GBP
- Report
- September 2025
- 85 Pages
India
From €3153EUR$3,500USD£2,782GBP
- Report
- January 2025
- 82 Pages
Vietnam
From €3153EUR$3,500USD£2,782GBP
- Report
- December 2024
- 87 Pages
Spain
From €3153EUR$3,500USD£2,782GBP
- Report
- October 2024
- 82 Pages
India
From €3153EUR$3,500USD£2,782GBP
- Report
- August 2024
- 80 Pages
Spain
From €3153EUR$3,500USD£2,782GBP
- Report
- August 2024
- 82 Pages
Japan
From €3153EUR$3,500USD£2,782GBP
- Report
- August 2024
- 80 Pages
Saudi Arabia
From €3153EUR$3,500USD£2,782GBP
- Report
- July 2024
- 80 Pages
Japan
From €3153EUR$3,500USD£2,782GBP

Macular Degeneration is a condition that affects the central part of the retina, known as the macula, which is responsible for sharp, central vision. It is the leading cause of vision loss in people over the age of 50. Optical treatments for Macular Degeneration include laser photocoagulation, photodynamic therapy, and anti-VEGF injections. Laser photocoagulation is used to reduce the risk of further vision loss by sealing off leaking blood vessels in the macula. Photodynamic therapy is used to reduce the growth of abnormal blood vessels in the macula. Anti-VEGF injections are used to reduce the growth of abnormal blood vessels and improve vision.
Companies in the Macular Degeneration market include Novartis, Regeneron, Allergan, Genentech, and Roche. Show Less Read more